Halozyme Therapeutics HALO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $376.71M+42.2% | $451.77M+51.6% | $354.26M+22.1% | $325.72M+40.8% | $264.86M+35.2% | ||
| $79.24M+63.7% | $78.77M+87.3% | $55.24M+11.8% | $46.36M+17.0% | $48.4M+70.9% | ||
| $297.47M+37.4% | $373M+45.7% | $299.02M+24.3% | $279.36M+45.7% | $216.46M+29.2% | ||
| 79%-2.8pp | 82.6%-3.3pp | 84.4%+1.4pp | 85.8%+2.9pp | 81.7%-3.8pp | ||
| $25.56M+72.7% | $31.9M+56.0% | $17.25M-6.5% | $17.54M-16.6% | $14.8M-22.6% | ||
| $57.88M+36.6% | $77.03M+82.3% | $46.09M+11.8% | $41.61M+16.5% | $42.36M+20.6% | ||
| $16.64M+55.9% | —— | $12.16M-3.3% | $12.16M+28.4% | $10.67M+8.1% | ||
| $3.1M+55.0% | —— | $2.1M+5.0% | $2M0.0% | $2M0.0% | ||
| $4.22M+57.1% | $68.58M+8.1% | $2.7M+3.8% | $2.7M+3.8% | $2.69M+10.0% | ||
| —— | $12.18M— | $12.18M— | $12.18M— | $12.18M— | ||
| $192.19M+55.8% | $544.66M+345% | $136.34M+7.5% | $123.28M+8.0% | $123.33M+22.9% | ||
| $184.52M+30.4% | —— | $217.92M+33.5% | $202.44M+72.7% | $141.54M+48.1% | ||
| 49%-4.5pp | —— | 61.5%+5.3pp | 62.2%+11.5pp | 53.4%+4.7pp | ||
| $5.51M+21.7% | $4.91M+8.2% | $4.3M-5.0% | $4.39M-2.9% | $4.53M+0.4% | ||
| $1.32M-80.7% | $2.43M-66.5% | $5.33M-17.6% | $6.89M+36.9% | $6.82M+36.6% | ||
| $180.33M+25.4% | —— | $218.96M+32.6% | $204.94M+74.1% | $143.83M+49.8% | ||
| $30.28M+17.7% | $40.74M-1.1% | $43.73M+55.4% | $39.78M+62.4% | $25.73M+34.0% | ||
| $150.05M+27.1% | —— | $175.23M+27.9% | $165.16M+77.1% | $118.1M+53.7% | ||
| 39.8%-4.8pp | —— | 49.5%+2.2pp | 50.7%+10.4pp | 44.6%+5.4pp | ||
| $1.22+31.2% | —— | $1.43+36.2% | $1.33+84.7% | $0.93+55.0% | ||
| $1.27+32.3% | —— | $1.49+38.0% | $1.36+86.3% | $0.96+57.4% | ||
| 122.9M-3.0% | 123.9M-4.3% | 122.3M-6.0% | 124.2M-3.9% | 126.6M-1.7% | ||
| 118.1M-4.1% | 119.8M-5.5% | 117.2M-7.6% | 121.3M-4.5% | 123.2M-2.9% | ||
| $30K-98.2% | —— | $357K-88.6% | $1.13M-62.6% | $1.71M-27.7% | ||
| $17M+59.3% | —— | $12.16M-3.3% | $12.16M+28.4% | $10.67M+8.1% | ||
| $16.64M+55.9% | —— | $12.16M-3.3% | $12.16M+28.4% | $10.67M+8.1% | ||
| $2.25M+21.6% | —— | $1.86M+0.9% | $1.85M+0.9% | $1.85M+0.9% | ||
| $29.51M+66.2% | $23.38M+31.6% | $17.76M0.0% | $17.76M0.0% | $17.76M0.0% | ||
| 27.9M+15.8% | —— | 21.9M-8.8% | 24.4M-8.6% | 24.1M-14.5% | ||
| $1.75M+258% | $84K— | $537K— | —— | $488K-67.8% | ||
| $175.59M+190% | —— | $357.8M— | -$114.47M-593% | $60.48M+30.7% | ||
| $155.44M+40.2% | —— | $181.37M+37.3% | $140.17M+51.3% | $110.85M+31.0% | ||
| -$214K+15.4% | —— | -$170K+52.0% | -$257K+11.1% | -$253K-15.0% | ||
| $0.17-6.1% | —— | $0.2+18.1% | $0.19-5.4% | $0.18-10.5% | ||
| $1.96M— | —— | $0— | $0— | $0— | ||
| -$24.92M-370% | $33.85M-32.6% | -$7.16M+69.1% | -$29.69M-2,377% | $9.22M-50.7% | ||
| $19.55M+610% | $90.48M+298% | $29.7M-58.3% | $11.72M-37.1% | -$3.83M+90.0% | ||
| -$3.43M-220% | —— | -$27.35M-9,268% | $7.09M+150% | $2.86M+321% | ||
| -$27.38M-4,772% | -$18.78M-343% | $1.1M— | $14.54M-32.1% | $586K-98.5% | ||
| $9.11M+82.3% | —— | $20.32M+153% | $36.07M-17.2% | $5M+204% | ||
| -$1.61M+51.4% | —— | -$22.4M-221% | -$298.97M-3,253% | -$3.32M-579% | ||
| -$2.88M+96.8% | -$741.79M— | $201.61M+220% | —— | -$90.42M-9.4% | ||
| $180.08M+16.8% | $219.03M+22.7% | $178.6M+54.8% | $99.71M+78.7% | $154.22M+19.2% | ||
| 10.0% | —— | —— | —— | 10.0% | ||
| $700K+40.0% | —— | $600K+20.0% | $500K-16.7% | $500K-16.7% | ||
| $2.9M+61.1% | —— | $1.9M+18.8% | $1.8M+5.9% | $1.8M0.0% | ||
| $2.6M+73.3% | —— | $1.5M+7.1% | $1.5M+7.1% | $1.5M+7.1% | ||
| $5.39M+174% | —— | $6.15M+226% | -$24.99M-4,194% | -$7.24M-193% | ||
| $1.33M+737% | —— | $2.17M+596% | $2.1M+525% | -$208K+59.8% | ||
| $4.02M+156% | —— | $3.67M+153% | -$27.05M-35,688% | -$7.22M-184% | ||
| $45K— | —— | -$3K-250% | -$3K+80.0% | $0-100% | ||
| -$3K-102% | —— | $312K-82.0% | -$35K+76.7% | $189K+160% | ||
| $1.32M-80.7% | $2.43M-66.5% | $5.33M-17.6% | $6.89M+36.9% | $6.82M+36.6% | ||
| —— | —— | —— | —— | —— | ||
| $1.61M-51.4% | —— | —— | —— | $3.32M+579% | ||
| $8.85M-93.7% | $0-100% | $4.96M-98.4% | $102.76M+10.0% | $139.64M-29.7% | ||
| $3.74M+294% | $1.43M-53.2% | $3.03M+99.7% | $1.56M-39.5% | $950K-73.2% | ||
| $710K— | —— | —— | —— | $0— | ||
| $9M-82.1% | —— | $209.6M+51.9% | $189.11M+250% | $50.17M-58.1% | ||
| —— | $71.22M— | $71.22M— | $71.22M— | $71.22M— | ||
| —— | $20.37M+3.1% | $20.37M+3.1% | $20.37M+3.1% | $20.37M+3.1% | ||
| $376.71M+42.2% | $451.77M+51.6% | $354.26M+22.1% | $325.72M+40.8% | $264.86M+35.2% | ||
| 100.0% | —— | —— | —— | 10+42.9% | ||
| $16.64M+55.9% | $16.57M+44.6% | $12.16M-3.3% | $12.16M+28.4% | $10.67M+8.1% | ||
| 300K-25.0% | —— | —— | —— | 400K-20.0% | ||
| 3.8%-0.5% | —— | 3.8%-0.6% | 3.8%-0.9% | 4.3%+0.1% | ||
| 3.6%-0.7% | —— | 3.7%+0.1% | 3.8%-0.8% | 4.3%+0.5% | ||
| 0%— | —— | 0%— | 0%— | 0%— | ||
| -$1.61M+51.4% | —— | $16.48M-11.2% | $4.52M-52.3% | -$3.32M-579% | ||
| —— | —— | $38.84M— | $306.38M— | -$244K— | ||
| $184.52M+30.4% | —— | $217.92M+33.5% | $202.44M+72.7% | $141.54M+48.1% | ||
| $188.74M+30.9% | —— | $220.62M+33.1% | $205.14M+71.2% | $144.22M+47.2% | ||
| $188.74M+30.9% | —— | $220.62M+33.1% | $205.14M+71.2% | $144.22M+47.2% | ||
| 50.1%-4.4pp | —— | 62.3%+5.1pp | 63%+11.2pp | 54.5%+4.4pp | ||
| $184.52M+30.4% | —— | $217.92M+33.5% | $202.44M+72.7% | $141.54M+48.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Halozyme Therapeutics's revenue?
- Halozyme Therapeutics (HALO) generated $1.5B in revenue over the trailing twelve months, up 39.1% year over year.
- Is Halozyme Therapeutics profitable?
- Halozyme Therapeutics reported $608.5M in net income over the trailing twelve months, a 47.9% net margin.
- What are Halozyme Therapeutics's profit margins?
- Gross margin is 82.8% and operating margin is 59.3%, with a 47.9% net margin.
- What is Halozyme Therapeutics's earnings per share?
- Halozyme Therapeutics's diluted EPS over the trailing twelve months is $4.91.
- Where does Halozyme Therapeutics's income statement data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
